TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03714620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
Study: NCT03350165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: 0.2mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: K-877 matching placebo tablet
Study: NCT00082342

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Phoressor II (IOMED)
Description: sham stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoressor II (IOMED)
Description: real tDCS stimulation
Study: NCT04045548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study: NCT03475680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gentamycin
Description: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gentamycin
Description: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ornidazole
Description: Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ornidazole
Description: Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Gentamycin
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Gentamycin
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Ornidazole
Description: Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Ornidazole
Description: Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1
Study: NCT04406974

Intervention type: PROCEDURE
Intervention: Surgery or treatment for local recurrence
Description: Surgery or treatment for local recurrence

Intervention type: PROCEDURE
Intervention: Surgery or treatment for local recurrence
Description: Surgery or treatment for local recurrence

Intervention type: PROCEDURE
Intervention: Surgery for advanced colorectal cancer
Description: Surgery for advanced colorectal cancer

Intervention type: PROCEDURE
Intervention: Surgery for advanced colorectal cancer
Description: Surgery for advanced colorectal cancer
Study: NCT02970916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI+aflibercept
Description: Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)
Study: NCT01966601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #1
Description: TRV027 continuous intravenous infusion Dose #1
Study: NCT00915005

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy
Description: Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy
Description: Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete.
Study: NCT04220775

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03815552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense Continuous Glucose Monitoring
Description: The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
Study: NCT06638736

Intervention type: OTHER
Group type: OTHER
Intervention: Wound Closure with sutures vs staples
Description: Closure of the wound with either sutures or staples depending upon the study arm

Intervention type: OTHER
Group type: OTHER
Intervention: Wound Closure with sutures vs staples
Description: Closure of the wound with either sutures or staples depending upon the study arm
Study: NCT00915005

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.
Study: NCT04409587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart
Description: A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion.
Study: NCT01305876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga intervention
Description: yoga session 2 x week over 3-1/2 months
Study: NCT01899326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04063670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Intervention
Description: Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine, Standard-of-Care
Study: NCT02452879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Electroacupuncture
Description: with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
Study: NCT06338423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vacuum mattress
Description: vacuum mattresses used to better positioning of the patient

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Mattress
Description: Standard Mattress
Study: NCT01966601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #2
Description: TRV027 continuous intravenous infusion Dose #2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #3
Description: TRV027 continuous intravenous infusion Dose #3
Study: NCT03126630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00915005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.
Study: NCT03126630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01966601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous intravenous infusion
Study: NCT00915005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein 1 time each week for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein 1 time each week for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein 1 time each week for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein 1 time each week for 7 weeks.
Study: NCT03912922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity regime
Description: Activity regime of 4 days followed by a test day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity regime
Description: Activity regime of 4 days followed by a test day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity regime
Description: Activity regime of 4 days followed by a test day.
Study: NCT04151537

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Activity Intelligence
Description: The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Guidelines
Description: The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
Study: NCT02332356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine or adalimumab and infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine or adalimumab and infliximab
Study: NCT01630044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM device
Description: Non-invasive neurostimulator, home-use treatment for up to 43 days.
Study: NCT04511234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagicTouch PTA sirolimus drug coated balloon (DCB)
Description: For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA standard balloon
Description: For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
Study: NCT02017678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: 5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
Study: NCT04443127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training Session
Description: VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor-Relearning Program
Description: Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
Study: NCT01831934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
Study: NCT01255397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Male Infertility Protocol
Description: 1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple.
Study: NCT01364571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine low dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
Study: NCT05220969

Intervention type: GENETIC
Intervention: Total Genotype Risk Score
Description: A total genotype risk score has been generated based on the results of previously observed genetic association studies
Study: NCT03620617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry supplement
Description: During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
Study: NCT03498066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blockers withdrawal
Description: withdrawal of all type of betablockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of the Betablockers (βB) treatment
Description: Use Betablockers treatment
Study: NCT04242550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Function- Enhanced CBT for BED (EF-BED+CBT)
Description: EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED.
Study: NCT02020187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on a cycle-ergometer
Description: Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
Study: NCT02806531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses enterovirus 71 vaccine
Description: Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
Study: NCT00809848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.075%
Description: AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.05%
Description: AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.025%
Description: AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-210669 vehicle ophthalmic solution
Description: AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
Study: NCT00994929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neumega (Oprelvekin, Interleukin 11, IL-11)
Description: 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
Study: NCT03378661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: E1224 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: E1224 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E1224 Placebo
Description: E1224 matched placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole Placebo
Description: Benznidazole matched placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole Placebo
Description: Benznidazole matched placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole Placebo
Description: Benznidazole matched placebo tablets